NICE announces development of Quality Standards on breast cancer and end of life care

NICE has announced the development of nine new Quality Standards, including one for the management of breast cancer and one on end of life care, during 2010/11.

NICE Quality Standards are markers of excellent care. They are produced collaboratively with the NHS and social care professionals, along with their partners and service users. They are derived from the best available evidence, usually NICE guidance or other sources that have been accredited by NHS Evidence. Quality standards set out the structures and processes of care, as well as the best outcomes for patients that the standard is likely to bring about.

Further information about Quality Standards is available on the NICE website or by clicking here.

Page published: Fri 13 August 2010

It is supported by 12 companies:

  • Amgen
  • Astra Zeneca
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • GE Healthcare
  • GSK
  • Lilly
  • Novartis
  • Pfizer
  • Roche
  • Sanofi Aventis